We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
-5.29%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$113M
AUM Growth
–
Cap. Flow
+$126M
Cap. Flow %
111.32%
Top 10 Hldgs %
77.87%
Holding
19
New
19
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
WVE icon
Wave Life Sciences
WVE
+$22.1M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$19.9M
3
LRMR icon
Larimar Therapeutics
LRMR
+$14.7M
4
ALDR
Alder Biopharmaceuticals
ALDR
+$7.77M
5
OREX
Orexigen Therapeutics, Inc.
OREX
+$7.15M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 78.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WVE icon
1
Wave Life Sciences
WVE
$1.13B
$22.5M 19.95%
+1,410,689
New +$22.1M
GBT
2
DELISTED
Global Blood Therapeutics, Inc.
GBT
$14.9M 13.19%
+460,000
New +$19.9M
ALDR
3
DELISTED
Alder Biopharmaceuticals
ALDR
$7.59M 6.73%
+229,895
New +$7.77M
EPZM
4
DELISTED
Epizyme, Inc
EPZM
$7.4M 6.56%
+461,651
New +$6.84M
LRMR icon
5
Larimar Therapeutics
LRMR
$398M
$6.92M 6.13%
+91,642
New +$14.7M
AIMT
6
DELISTED
Aimmune Therapeutics
AIMT
$6.55M 5.81%
+355,020
New +$6.57M
RGLS
7
DELISTED
Regulus Therapeutics
RGLS
$6.27M 5.56%
+5,992
New +$6.01M
AERI
8
DELISTED
Aerie Pharmaceuticals
AERI
$5.67M 5.03%
+232,757
New +$5.43M
OREX
9
DELISTED
Orexigen Therapeutics, Inc.
OREX
$5.16M 4.58%
+300,000
New +$7.15M
XLRN
10
PUT
DELISTED
Acceleron Pharma
XLRN
$4.88M 4.32%
+100,000
New +$3.6M
XENT
11
DELISTED
Intersect ENT, Inc
XENT
$4.5M 3.99%
+200,000
New +$3.95M
NDRM
12
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$4.47M 3.96%
+261,945
New +$5.1M
LPCN icon
13
Lipocine
LPCN
$17.6M
$4.27M 3.78%
+19,412
New +$4.07M
AKTX
14
Akari Therapeutics
AKTX
$14.8M
$3.83M 3.39%
+330
New +$4.9M
XLRN
15
DELISTED
Acceleron Pharma
XLRN
$2.44M 2.16%
+50,047
New +$1.8M
DYAX
16
CALL
DELISTED
DYAX CORPORATION
DYAX
$2.1M 1.87%
+55,900
New +$1.8M
RGNX icon
17
Regenxbio
RGNX
$615M
$1.66M 1.47%
+100,000
New +$1.98M
DMTX
18
DELISTED
Dimension Therapeutics, Inc
DMTX
$1.11M 0.98%
+98,297
New +$1.24M
IMGN
19
DELISTED
Immunogen Inc
IMGN
$581K 0.52%
+42,815
New +$527K

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q4 2015 Portfolio in Review

Q4 2015 is the first quarter with a 13F filing on record for Foresite Capital Management III, which disclosed 19 positions worth $113M. Its ten largest holdings account for 78% of the portfolio.

Its largest position is Wave Life Sciences: 1,410,689 shares worth $22.5M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets.

  • Foresite Capital Management III's largest Q4 2015 buy was Wave Life Sciences: 1,410,689 shares worth $22.5M.
  • Foresite Capital Management III's ten largest holdings make up 78% of its $113M portfolio in Q4 2015.
  • Foresite Capital Management III disclosed 19 positions in Q4 2015, its first 13F filing on record.

Based on Foresite Capital Management III's 13F filing for Q4 2015, filed 12 Feb 2016.